Lumipulse® G PIVKA-II

Immunoreaction cartridges for in vitro diagnostic (IVD) use with the LUMIPULSE G System for the quantitative measurement of protein induced vitamin K absence or antagonist-II (PIVKA-II) in serum.

The assay utilises proven CLEIA (ChemiLuminescent Enzyme Immunoassay) technology with results that are available in up to 35 minutes.

    CE marked
    Lumipulse® G PIVKA-II Immunoreaction Cartridges

    Product number 233184

    3 x 14 Tests
    Lumipulse® G PIVKA-II Calibrators Set

    Product number 233191

    2 x 3 x 1.5 ml
    Please contact your local Fujirebio representative for the availability of this product in your country.

    Click here to navigate

    • Contact sales for information
    • Details
    • Conditions of sale
    • Documentation
    • Insights
    • FAQ
    • Related products
    • Product inquiry
    • Details

      Product benefits

      • Allows stratification of patients on transplant waiting list.
      • Predicts recurrence of HCC.
      • Complementary to AFP for improved detection of (early) HCC. 

      Complete Solution:

      • CE-marked

      • Only assay available on an automated platform (LUMIPULSE G1200)

      • Oncology menu available for routine, specialized and unique markers

      • Chemiluminescent assay

      • Calibrators and controls available

      Different clinical applications:

      • Monitoring: Correlation with microvascular invasion, recurrence and tumor size

      • Diagnosis: Complementary to AFP for the improved detection of HCC

      Clinical background  

      Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide with a high rate of mortality and an increasing incidence.

      The most common causes of HCC are either a viral hepatitis infection (hepatitis B or C) or cirrhosis (alcoholism being the most common cause of hepatic cirrhosis).

      The starting point in the diagnostic surveillance of at risk patients is ultrasound.

      In a second stage this can be completed with the measurement of a tumor marker called α-fetoprotein (AFP).

      Since ultrasound has a poor performance in cirrhotic patients and is also operator dependent, further characterization by CT or MRI is often required.

      As it is important to detect HCC at an early stage when the disease is still curable, biomarkers can complete the diagnosis obtained with ultrasound before moving on to the more expensive MRI.

      Biomarkers can also be used to better stratify patients on the liver transplant waiting list.

      Additionally, the risk of recurrence of HCC after transplantation can be assessed by monitoring patients with biomarkers.

      Assay technology

      CLEIA - ChemiLuminescent Enzyme Immunoassay 


      See the LUMIPULSE G1200 working in this video:



    • Conditions of sale

      To read the end user conditions of sale for this product please visit our Resource center.

    • FAQ

    • Product inquiry

      The provision of your data implies your consent to the processing of your data in our database and, depending on the option you choose, to receiving our monthly newsletter by e-mail.

      For more information on how we process your personal data and regarding the rights you have in this respect, we refer to our privacy policy, which we hold at your disposal HERE.

      If you no longer wish to receive our newsletter, you have the option to unsubscribe via the ‘unsubscribe’ tool at the bottom of the newsletter. If you want to have your data removed from our database, please contact us at: